Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575023 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL29049316 | 0.80 | SMN1; SMN2 (0.31) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3852439 | 0.80 | ALDH1A1 (0.32) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL476049 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL8764997 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL12567309 | 0.78 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL11158482 | 0.78 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL10965455 | 0.78 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL10873860 | 0.78 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL1985795 | 0.78 | CA1 (0.35) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-18 | — | — | US | claimed |
| WO-2024145600-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-04 | — | — | WO | claimed |
| US-20200190199-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-06-18 | — | — | US | claimed |
| EP-2032172-B1 | LEPTOMYCIN DERIVATIVES | SANOFI SA (FR) | 2012-06-06 | — | — | EP | claimed |
| EP-2386559-A1 | Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-11-16 | — | — | EP | claimed |
| US-20110254808-A1 | REFLECTIVE TOUCH DISPLAY PANEL AND MANUFACTURING METHOD THEREOF | AU OPTRONICS CORPORATION (TW) | 2011-10-20 | — | — | US | claimed |
| EP-1813614-B1 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI SA (FR) | 2011-10-05 | — | — | EP | claimed |
| US-20110002947-A1 | LEPTOMYCIN DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | US | claimed |
| US-7514078-B2 | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-18 | — | — | US | disclosed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024145600-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-04 | — | — | WO | disclosed |
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | IMMUNOGEN, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240190956-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-1998016257-A2 | STABILIZED MICROPARTICLES AND THEIR USE AS ULTRASOUND CONTRAST AGENTS | MOLECULAR BIOSYSTEMS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| EP-0425235-B1 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5416064-A | Antitumor agents | IMMUNOGEN, INC. (US) | 1995-05-16 | — | — | US | disclosed |
| EP-0404783-A4 | IMMUNOASSAYS USING MONOCLONAL ANTIBODIES DIRECTED AGAINST NATURAL BINDING PROTEINS | — | 1991-01-23 | — | — | EP | disclosed |
| EP-0404783-A1 | IMMUNOASSAYS USING MONOCLONAL ANTIBODIES DIRECTED AGAINST NATURAL BINDING PROTEINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| WO-1989007271-A1 | IMMUNOASSAYS USING MONOCLONAL ANTIBODIES DIRECTED AGAINST NATURAL BINDING PROTEINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MKI67, GABBR1, GABBR2 | SMN1; SMN2 3393/4885ALDH1A1 540/4885TSHR 879/4885 |
| US-20240190956-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | SMN1; SMN2 1659/4885ALDH1A1 96/4885TSHR 3064/4885 |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | SIGLEC7, FUT5, FUT6 | SMN1; SMN2 3681/4885ALDH1A1 549/4885TSHR 1046/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | SMN1; SMN2 2467/4885ALDH1A1 2452/4885TSHR 79/4885 |
| US-20110002947-A1 | LEPTOMYCIN DERIVATIVES | CLSPN, CD47, HCLS1 | SMN1; SMN2 949/4885ALDH1A1 3948/4885TSHR 2217/4885 |
| US-20200190199-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4751/4885ALDH1A1 3084/4885TSHR 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.